Veradermics, Inc
Veradermics (MANE) and Absci (ABSI) shares have surged as investors bet on the hair-loss drug market. Veradermics reported positive trial results for an oral minoxidil tablet, while Absci is developing an AI-designed injectable treatment. Both companies face competition and clinical risks, with no new FDA-approved hair-loss drug since the 1990s.
Veradermics Inc (MANE) fell 4.8% to $97.9, hitting a low of $93.81, due to insider selling and dilution concerns. CEO and directors sold significant shares, and the company reported a wider Q2 2026 loss of $23.5M. Analysts maintain bullish targets, but broader market weakness also pressured the stock.
Veradermics Inc (MANE) shares dropped 4.8% on Monday after Montanova Capital sold 750,000 shares at $107.25 each, as disclosed in an SEC filing. Montanova Capital remains a significant shareholder, holding 3.1 million shares indirectly. David Friedman, a Montanova Capital executive, serves on Veradermics' board.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MANE (Veradermics, Inc). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent MANE coverage spans insider activity, market movers and sector analysis.
In the last 30 days, MANE insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($80.4M). The most active reporter was MONTANOVA CAPITAL, LLC with 2 filings.
Strong trial data reduces clinical risk but valuation already high; upside limited by early‑stage status.
Bearish pressure from insider liquidation and increased share supply.
The insider sale suggests negative sentiment and potential further downside.
Significant insider sell may signal lack of confidence, pressure on stock price.
Insider selling is disclosed, but the presence of a pre-arranged 10b5-1 plan reduces signal strength versus discretionary selling.
AlphAI scores every news story that mentions MANE with an AI model for sentiment and relevance, and aggregates insider trades from Veradermics, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Veradermics (MANE) and Absci (ABSI) shares have surged as investors bet on the hair-loss drug market. Veradermics reported positive trial results for an oral minoxidil tablet, while Absci is developing an AI-designed injectable treatment. Both companies face competition and clinical risks, with no new FDA-approved hair-loss drug since the 1990s.
2 min readVeradermics Inc (MANE) fell 4.8% to $97.9, hitting a low of $93.81, due to insider selling and dilution concerns. CEO and directors sold significant shares, and the company reported a wider Q2 2026 loss of $23.5M. Analysts maintain bullish targets, but broader market weakness also pressured the stock.
2 min readVeradermics Inc (MANE) shares dropped 4.8% on Monday after Montanova Capital sold 750,000 shares at $107.25 each, as disclosed in an SEC filing. Montanova Capital remains a significant shareholder, holding 3.1 million shares indirectly. David Friedman, a Montanova Capital executive, serves on Veradermics' board.
2 min readMONTANOVA CAPITAL, LLC sold 750,000 indirectly-held shares of Veradermics, Inc (MANE) at $107.25 ($80.44M total) across 2 trades on 2026-08-19. Filed jointly with Cowen Aaron, Averill Master Fund, Ltd. (Director) and Averill Madison Master Fund, Ltd. (Director).
1 min readDurso Timothy August (Chief Technical Officer) sold 43,500 shares of Veradermics, Inc (MANE) at an average of $107.82 ($106.71–$111.28, $4.69M total) across 5 trades on 2026-08-17 under a Rule 10b5-1 trading plan.
2 min readWaldman Reid Alexander (Chief Executive Officer) sold 67,500 shares of Veradermics, Inc (MANE) at an average of $107.86 ($106.72–$111.28, $7.28M total) across 5 trades on 2026-08-17 under a Rule 10b5-1 trading plan.
2 min readCHILDS JOHN W sold 100,000 indirectly-held shares of Veradermics, Inc (MANE) at an average of $107.12 ($106.14–$108.24, $10.71M total) across 3 trades on 2026-08-12.
2 min readVeradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair gr
6 min readInvesting.com reports Friday’s market weakness, with Nasdaq down about 1% and stocks set for a weekly loss. It lists major movers including Micron Tech (MU) up 3.66%, Oracle (ORCL) up 2.7%, and Coca-Cola (KO) down 4.66% after fairlife suspends US production following a cyberattack. Other cited moves include Applied Materials (AMAT) down 4.3% and SpaceX (SPCX) down 4.07%.
4 min readBiotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
7 min read
